ALLR

Allarity Therapeutics
ALLR

$0.20
2.26%
 

About: Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.

Employees: 6

0
Funds holding %
of 6,702 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

200% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 0

0% more funds holding

Funds holding: 4 [Q4 2023] → 4 (+0) [Q1 2024]

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0.36% less ownership

Funds ownership: 0.99% [Q4 2023] → 0.63% (-0.36%) [Q1 2024]

63% less capital invested

Capital invested by funds: $31.8K [Q4 2023] → $11.7K (-$20.1K) [Q1 2024]

Research analyst outlook

We haven’t received any recent analyst ratings for ALLR.

Financial journalist opinion